Silva Tricya N V, de Marchi Daniel, Mendes Marcela L, Barretti Pasqual, Ponce Daniela
Botucatu School of Medicine, University of São Paulo State-UNESP, Botucatu, São Paulo, Brazil.
Hemodial Int. 2014 Jan;18(1):15-23. doi: 10.1111/hdi.12071. Epub 2013 Aug 14.
Vascular access is the major risk factor for bacteremia, hospitalization, and mortality among hemodialysis (HD) patients. The type of vascular access most associated with bloodstream infection is central venous catheter (CVC). The incidence of catheter-related bacteremia ranges between 0.6 and 6.5 episodes per 1000 catheter days and increases linearly with the duration of catheter use. Given the high prevalence of CVC use and its direct association with catheter-related bacteremia, which adversely impacts morbidity and mortality rates and costs among HD patients, several prevention measures aimed at reducing the rates of CVC-related infections have been proposed and implemented. As a result, a large number of clinical trials, systematic reviews, and meta-analyses have been conducted in order to assess the effectiveness, clinical applicability, and long-term adverse effects of such measures. In the following article, prophylactic measures against CVC-related infections in HD patients and their possible advantages and limitations will be discussed, and the more recent literature on clinical experience with prophylactic antimicrobial lock therapy in HD CVCs will be reviewed.
血管通路是血液透析(HD)患者发生菌血症、住院和死亡的主要危险因素。与血流感染最相关的血管通路类型是中心静脉导管(CVC)。导管相关菌血症的发生率为每1000个导管日0.6至6.5次发作,并随导管使用时间呈线性增加。鉴于CVC使用的高普及率及其与导管相关菌血症的直接关联,这对HD患者的发病率、死亡率和成本产生不利影响,因此已经提出并实施了一些旨在降低CVC相关感染率的预防措施。结果,为了评估这些措施的有效性、临床适用性和长期不良反应,已经进行了大量的临床试验、系统评价和荟萃分析。在以下文章中,将讨论针对HD患者CVC相关感染的预防措施及其可能的优点和局限性,并回顾关于HD CVC预防性抗菌封管治疗临床经验的最新文献。